



**RANBAXY**

**Daiichi Sankyo Group to Expand its Business Scope in Japan through  
Establishment of Daiichi Sankyo Espha Co., Ltd.**

**February 26, 2010, Tokyo, Japan and Gurgaon, India** - Daiichi Sankyo Company Limited (“Daiichi Sankyo”) and Ranbaxy Laboratories Limited (“Ranbaxy”) today announced that Daiichi Sankyo will establish Daiichi Sankyo Espha Co., Ltd. (“Daiichi Sankyo Espha”) on April 1<sup>st</sup>, 2010. Daiichi Sankyo Espha will market generic drugs, as well as Daiichi Sankyo’s products which have gained a well-established reputation in the market.

*“Daiichi Sankyo is dedicated to meeting the universal desire of patients to improve their health and better balance their lives,”* said Takashi Shoda, President & CEO of Daiichi Sankyo. *“We believe that our understanding of the Japanese market and local presence united with the global expertise of Ranbaxy in the generic arena will enable us to achieve efficient and immediate entry into the generic market.”*

Remarking on the development, Atul Sobti, CEO and Managing Director of Ranbaxy, said, *“Daiichi Sankyo’s leadership in the Japanese pharmaceutical market will guide us to further expand our business in Japan. Ranbaxy is committed to bringing high quality, affordable medicines to doctors and patients across the world.”*

Completing their strategic alliance in November 2008 to form the unique Hybrid Business Model, Daiichi Sankyo and Ranbaxy (collectively “the Group”) have been moving forward to fully leverage the Model. The expanded global reach enables leading market positions in both developed and emerging markets through the supply of innovative and established pharmaceuticals.

In addition to meeting unmet medical needs through the development and marketing of outstanding new drugs, the Group also operates an OTC business, and is accelerating its efforts to reinforce its Vaccine business. In order to further fulfill the various needs patients have, the Group is also committed to providing patients with reliable generic pharmaceuticals through a strong network of Japanese and overseas companies. Leveraging Ranbaxy’s strengths, Daiichi Sankyo Espha will expand its product pipeline and continuously realize stable supply.

As a member of the Group, Daiichi Sankyo Espha will continue to respond to the expectations of patients, firmly coordinating the Group's strengths through coordination of the most important elements of pharmaceuticals: quality, information, and stable supply.

#### Profile of Daiichi Sankyo Espha

Company Name:	Daiichi Sankyo Espha Co., Ltd.	
Main Business:	Manufacturing and sales of pharmaceuticals	
Capital:	¥450 million	
Headquarters:	1-16-13, Kitakasai, Edogawa-ku, Tokyo, Japan	
Expected Date of Establishment:	April 1, 2010	
Member of the Board and Auditor:		
<u>Title</u>	<u>Name</u>	<u>Current Position</u>
Representative Director and Chairman	Ryuzo Takada	Member of the Board, Senior Executive Officer, Daiichi Sankyo Co., Ltd.
Representative Director and President	Shinsei Tamai	Corporate Officer, Deputy Head of Sales & Marketing Division and General Manager of Sales Planning Department, Daiichi Sankyo Co., Ltd.
Member of the Board	Hirohito Yoshiwaka	General Manager of Promotion Management Department, Sales & Marketing Division, Daiichi Sankyo Co., Ltd.
Member of the Board	Sanjeev I. Dani	Senior Vice President & Regional Director – Asia, CIS & Africa., Ranbaxy Laboratories Limited
Corporate Auditor	Ryoichi Watanabe	General Manager of Corporate Finance & Accounting Department, Daiichi Sankyo Co., Ltd.

#### **About Daiichi Sankyo Company, Limited**

A global pharma innovator, Daiichi Sankyo Company, Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit [www.daiichisankyo.com](http://www.daiichisankyo.com).

#### **About Ranbaxy Laboratories Limited**

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its

customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.

For further information, please contact:

**Daiichi Sankyo Company, Limited**  
**3-5-1, Nihonbashi Honcho,**  
**Chuo-ku, Tokyo 103-8426, Japan**

Toshiaki Sai  
General Manager - Corporate Communications

Masaya Tamae  
Director - Public Relations

Shigemichi Kondo  
Director - Investor Relations

Tel: +81-3-6225-1126

**Ranbaxy Laboratories Limited**  
**Plot 90, Sector 32, Gurgaon**  
**Haryana 122001, India**

Ramesh L. Adige  
President - Corporate Affairs and  
Global Corporate Communications  
email: [ramesh.adige@ranbaxy.com](mailto:ramesh.adige@ranbaxy.com)  
Tel: +91-124-4135000

Raghu Kochar  
Director-Corporate Communications  
email: [raghu.kochar@ranbaxy.com](mailto:raghu.kochar@ranbaxy.com)  
Tel: +91-124-4135141  
Mobile: 9811617256

Krishnan Ramalingam  
General Manager-Corporate Communications  
email: [krishnan.ramalingam@ranbaxy.com](mailto:krishnan.ramalingam@ranbaxy.com)  
Tel: +91-124-4135143  
Mobile: 9810042540